Submission of Unaudited Standalone & Consolidated financial Result for the quarter and half year ended 30.09.2026

MEDI-CAPS LIMITED CIN: L70100MP1983PLC002231 MCL/SE/2026-2027 Date: 04.11.2026 Online filing at: www.listing.bseindia.com The General Manager DCS-CRD BSE Limited Phiroze Jeejeebhoy Towers, ‘A’ wing Dalal Street Fort, Mumbai — 400001 (M.H.) SUBJECT: OUTCOME OF BOARD MEETING HELD ON WEDNESDAY, 04™ NOVEMBER. 2026 PURSUANT TO REGULATION 30 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015. REFERENCE: MEDI-CAPS LIMITED (BSE SCRIP CODE: 523144, ISIN: INE442D01010) Dear Sir/Madam, With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board of Directors at their meeting held on today i.e. Wednesday 04" November, 2026 has inter alia considered and approved the following businesses: (1) Un-audited Standalone and Consolidated Financial Results of the Company for the quarter as well as half year ended on 30™ September, 2026 along with Statement of Assets and Liabilities, Cash Flow Statement and Limited Review Report thereon. (2) Other routine businesses with the permission of chair. Further, a copy of aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be submitted in XBRL (Integrated Filing Financial) mode within prescribed time limit. The aforesaid Un-Audited Standalone and Consolidated Financial Results shall also be uploaded on the Company’s website www.medicaps.com and on the website of the Stock Exchange at www.bseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers within prescribed time limit. The Meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 03.55 P.M. The above information will also be available on the website of the Company at www.medicaps.com. This is for your information and record. Thanking You, REGISTERED OFFICE 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE - 452001 PH:- 0731-4028148, FAX:- 0731-4041435 E mail:- investors@medicaps.com, Web site:- www.medicaps.com MEDI-CAPS LIMITED CIN: L70100MP1983PLC002231 Yours Faithfully, FOR MEDI-CAPS LIMITED ALOK K GARG CHAIRMAN & MANAGING DIRECTOR DIN: 00274321 Encl.: Un-audited Standalone and Consolidated Financial Results, Statements of Assets and Liabilities & Cash flow along with limited review report for quarter as well as half year ended on 30th September, 2026. REGISTERED OFFICE 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA INDORE - 452001 PH:- 07314028148, FAX:- 0731-4041435 E mail:- investors@medicaps.com, Web site:- www.medicaps.com RAWKA & ASSOCIATES CHARTERED ACFOI\NTA 412, Arcade lever 56, @ Off. LIMITED REVIEW REPORT Independent Auditor's Review Report for the Quarter and Half Year ended 30" September, 2026 on Unaudited Standalone Financial Results of Medi-Caps Limited (the Company) Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended THE BOARD OF DIRECTORS OF MEDI-CAPS LIMITED SCOPE OF THE REVIEW . We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of MEDI-CAPS LIMITED ("the Company") for the quarter and half year ended 30th September, 2026 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended (‘SEBI Listing Regulations’), including relevant circulars issued by the SEBI from time to time. ). The Statement is the responsibility of the Company's Management and has been approved by the Company's Board of Directors. Our responsibility is to issue a report on the Statement based on our review of the Statement, which has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34"), specified under Section 133 of the Companies Act, 2013 read with relevant rules issued there under, and other accounting principles generally accepted in India and in Compliance with Regulation 33 of the SEBI Listing Regulations. . We conducted our review of the Statement in accorda; Engagements (SRE) 2410, "Review of Interim Finai § v G Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analyticai and other review procedures. A review is substantiaily less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. CONCLUSION . Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance .wiih the recognition and measurement principles laid down in the applicable Indian accounting standards (‘Ind AS’) specified under Section 133 of the Companies Act, 2013 as amended. read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI Listing Regulations including the manner in which itis o be disclosed. or that it contains any material misstatement. Date: 04.11.2026 For: Rawka & Associates Place: Indore . Chartered Accountants UDIN: 26429040X1.PYPJ4894 . FRN -021606C VASEgs Venus Rawka Partner Membership No. 42504¢ MEDI-CAPS LIMITED REGD. OFFICE: 201, PUSHPRATNA PARADISE, 9/5 NEW PALASIYA, INDORE (M.P. 452001 PHONE: 0731-4028148 FAX: 0731-4041435 Website: www.medicaps.com Email: investors@medicaps.com CIN: L70100MP1983PLC002231 UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER/HALF ENDED 30.09.2026 (Amount in Lacs except EPS) Quarter Ended Hall Year Ended Year Ended ! sep 302026 | VUNE3OTHL | Gpp 3o 2025 | SEP30th2026 | SEP30th 2025 | Mar 31st,2026 Particulars 2026 Unaudited Unaudited Unaudited Unaudited Unaudited (Audited) T |Revenue from Operation () Net sales 1032 Zal 99.78 1474 99.78] 2843 (b) Other operating income 1.95 6.08 018 3.03 0.18] 216 Revenue from Operation 1227 10.49] 99.96 22.77] 99.96, 230.59 T__|Other Income 0.60 037 097 097 32.30) 57.65 1 Total income (I+11) 12.87] 10.86 100.93 23.74] 132.26; 288.24 v Expenses a) Cost of material consumed 0.00 000 0.00 0.00] 0.00 0.00 b) Purchase ofs tock in trade 0.00 0.00 0.00 0.00 0.00 0.00 ) Changes in inventories of finished goods, 0.02 0.01 015 0.03 015 0.33 work-in-progress and stock-in-trade d) Employee benefits expense 482 5438 45.90 99.20 9157 18532 ¢) Finance costs 0.00 0.00 0.00 0.00) 0.00 0.00 1) Depreciation and amortisation expense 465 465 4.00 9.29) 301 1858 2) Power Cost 0.18 0.29 0.37 0.47 0.94 3.55 h) Freight Exp. 0.00 0.00 0.00 0.00 0.00 0.00 i) Other expenses 15.88 1050 2186 2638, 42.68 9.9 ‘Total_Expenses (IV) 65.55/ 69.82] 7228 135.37] 143.35 300.70 v Profit/(Loss) before exceptional item & tax (111-1v) 52.68 5896 28.65 11163 1109 “12.46 VI_|Exceptional items 0.00 0.00 0.00 0.00) 0.00 0.00) VII_|Profit/ (Loss) before tax (V-VI) 52.68 5896 28.65] 11163 1109 12,46 VIII | Tax expense 1) Current Tax 0.00 000 0.00 0.00 0.00 0.00 2) Earlier year (excess)/Short provision for tax written back 0.00 0.00] 0.00 0.00 0.00 285 3) Deferred Tax 0.00 0.0 0.00 0.00 0.00 144 Total Tax Expenses 0.00 0.00 0.00 0.00 0.00 141 IX_|Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00 0.00 0.00 [Showing first 8,000 characters — download PDF for full document]